Physician profile
Susan Frances Julius
NPI 1407921935
$255,020.34
in general payments reported to CMS, 2019-2025
18 companies · $76K in 2025
The $76K reported for 2025 was more than what 99% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $638 · 2021: $776 · 2022: $33K · 2023: $45K · 2024: $99K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Travel and Lodging: $52K · Consulting Fee: $12K · Food and Beverage: $9,839 · Education: $38.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,223.91 |
| Travel and Lodging | $51,757.16 |
| Consulting Fee | $12,275.00 |
| Food and Beverage | $9,838.63 |
| Education | $38.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $241,874.18 | 2019-2025 | Epclusa, Biktarvy |
| Eli Lilly and Company | $6,402.34 | 2025 | |
| Vanda Pharmaceuticals INC. | $1,961.20 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $894.20 | 2019-2025 | |
| Axsome Therapeutics, INC. | $710.63 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $674.58 | 2022-2025 | Caplyta |
| Braeburn INC. | $534.62 | 2023-2025 | Brixadi |
| Alkermes, INC. | $485.51 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $386.80 | 2019-2023 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $326.15 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Uswm, LLC | $176.75 | 2023-2024 | Lucemyra, Zimhi |
| Janssen Pharmaceuticals, INC | $152.71 | 2025 | Invega Sustenna |
| Alfasigma USA, INC. | $149.07 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $141.52 | 2025 | Cobenfy |
| Hikma Pharmaceuticals USA | $53.04 | 2022-2024 | Kloxxado |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $45.10 | 2019-2023 | Zubsolv |
| Mdd US Operations, LLC | $36.22 | 2019 | |
| Pfizer INC. | $15.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Julius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.